Theralase Technologies IncOTCQB:TLTFFView on Canadian Exchange
- LAST PRICE0.1212
- TODAY'S CHANGE (%)-0.0030 (-2.4155%)
- Bid / Lots0.1207/ 120
- Ask / Lots0.1223/ 385
- Open / Previous Close0.1250 / 0.1242
- Day Range
- 52 Week Range
- Volume47,570
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLTFF |
|---|---|---|
| 09:34 ET | 7070 | 0.125 |
| 11:08 ET | 7000 | 0.1248 |
| 11:49 ET | 6000 | 0.1248 |
| 02:44 ET | 1000 | 0.1207 |
| 02:54 ET | 26500 | 0.1212 |
Yesterday
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement, from 7:02AM ET on Wednesday Apr 24, 2024 by Dow Jones
7:02AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 5, 2024
Theralase(R) Granted Canadian Cancer Vaccine Patent, from 7:02AM ET on Friday Apr 05, 2024 by Dow Jones
7:02AM ET on Friday Apr 05, 2024 by Dow Jones
Mar 27, 2024
Theralase(R) Release's 4Q2023 Interim Financial Statements, from 7:02AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:02AM ET on Wednesday Mar 27, 2024 by Dow Jones
Mar 26, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Theralase Technologies Inc | 36.9M | 0.0x | --- |
Company Information
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.
Contact Information
- Headquarters
- 41 Hollinger RoadTORONTO, ON, Canada M4B 3G4
- Phone
- 416-699-5273
- Fax
- 416-699-5250
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.9M |
|---|---|
Revenue (TTM) | $1.1M |
Shares Outstanding | 223.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.58 |
EPS | $-0.02 |
Book Value | $0.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 34.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -427.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
